Company / Current Liabilities
Anixa Biosciences Inc Current Liabilities History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$2.5M
FY2024
5-year range
$1.2M / $2.5M
FY2020-FY2024
Trend
+23.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $468,756 in FY2016 to $3M in FY2024.
Based on SEC 10-K filings.
$3M in FY2024 with a 10-year CAGR of +3.3%.
Increased from $2M to $3M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +11.0%
- 10-Year CAGR
- +3.3%
Key checks
Key Insights
- 5-year CAGR of +11.0%, indicating consistent growth.
- In FY2024, current liabilities increased 23.3% year-over-year.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.5M | +23.3% |
| FY2023 | $2.0M | -0.4% |
| FY2022 | $2.0M | +71.4% |
| FY2020 | $1.2M | -19.8% |
| FY2019 | $1.5M | +17.1% |
| FY2018 | $1.3M | +42.2% |
| FY2017 | $889.5K | +89.8% |
| FY2016 | $468.8K | -21.1% |
| FY2015 | $593.8K | -67.2% |
| FY2014 | $1.8M | -0.7% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026